Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 149

Similar articles for PubMed (Select 22076875)

1.

Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women.

Semba RD, Fink JC, Sun K, Cappola AR, Dalal M, Crasto C, Ferrucci L, Fried LP.

Clin J Am Soc Nephrol. 2012 Jan;7(1):85-91. doi: 10.2215/CJN.08070811. Epub 2011 Nov 10.

2.

Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.

Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Obi Y, Okada N, Tsubakihara Y, Isaka Y, Rakugi H.

Clin J Am Soc Nephrol. 2012 May;7(5):810-9. doi: 10.2215/CJN.08680811. Epub 2012 Feb 23.

3.

FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy.

Lundberg S, Qureshi AR, Olivecrona S, Gunnarsson I, Jacobson SH, Larsson TE.

Clin J Am Soc Nephrol. 2012 May;7(5):727-34. doi: 10.2215/CJN.10331011. Epub 2012 Mar 1.

4.

Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.

Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F; MMKD Study Group, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P.

J Am Soc Nephrol. 2007 Sep;18(9):2600-8. Epub 2007 Jul 26.

5.

Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.

Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, Serra AL.

Nephrol Dial Transplant. 2013 Feb;28(2):352-9. doi: 10.1093/ndt/gfs460. Epub 2012 Nov 4.

6.

Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.

Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, Mikami S, Inoue K, Shimomura A, Nagasawa Y, Okada N, Tsubakihara Y, Rakugi H, Isaka Y.

Bone. 2012 Jun;50(6):1266-74. doi: 10.1016/j.bone.2012.02.634. Epub 2012 Mar 6.

PMID:
22425694
7.

Regulation of fibroblast growth factor-23 in chronic kidney disease.

Westerberg PA, Linde T, Wikström B, Ljunggren O, Stridsberg M, Larsson TE.

Nephrol Dial Transplant. 2007 Nov;22(11):3202-7. Epub 2007 Jun 13.

9.

Serum bicarbonate concentrations and kidney disease progression in community-living elders: the Health, Aging, and Body Composition (Health ABC) Study.

Goldenstein L, Driver TH, Fried LF, Rifkin DE, Patel KV, Yenchek RH, Harris TB, Kritchevsky SB, Newman AB, Sarnak MJ, Shlipak MG, Ix JH; Health ABC Study Investigators.

Am J Kidney Dis. 2014 Oct;64(4):542-9. doi: 10.1053/j.ajkd.2014.05.009. Epub 2014 Jun 18.

PMID:
24953890
10.

Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs).

Westerberg PA, Tivesten Å, Karlsson MK, Mellström D, Orwoll E, Ohlsson C, Larsson TE, Linde T, Ljunggren Ö.

BMC Nephrol. 2013 Apr 15;14:85. doi: 10.1186/1471-2369-14-85.

11.

The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.

Taal MW, Thurston V, McIntyre NJ, Fluck RJ, McIntyre CW.

Kidney Int. 2014 Aug;86(2):407-13. doi: 10.1038/ki.2013.537. Epub 2014 Jan 15.

PMID:
24429404
12.

Disordered FGF23 and mineral metabolism in children with CKD.

Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB.

Clin J Am Soc Nephrol. 2014 Feb;9(2):344-53. doi: 10.2215/CJN.05840513. Epub 2013 Dec 5.

13.

Serum fibroblast growth factor-23 is associated with incident kidney disease.

Rebholz CM, Grams ME, Coresh J, Selvin E, Inker LA, Levey AS, Kimmel PL, Vasan RS, Eckfeldt JH, Feldman HI, Hsu CY, Lutsey PL; Chronic Kidney Disease Biomarkers Consortium.

J Am Soc Nephrol. 2015 Jan;26(1):192-200. doi: 10.1681/ASN.2014020218. Epub 2014 Jul 24.

PMID:
25060052
14.

Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.

Wan M, Smith C, Shah V, Gullet A, Wells D, Rees L, Shroff R.

Nephrol Dial Transplant. 2013 Jan;28(1):153-61. doi: 10.1093/ndt/gfs411. Epub 2012 Nov 23.

15.

Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD.

Stubbs JR, Zhang S, Friedman PA, Nolin TD.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1965-73. doi: 10.2215/CJN.03130314. Epub 2014 Sep 2.

PMID:
25183657
16.

Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.

Sánchez Fructuoso AI, Maestro ML, Pérez-Flores I, Valero R, Rafael S, Veganzones S, Calvo N, De la Orden V, De la Flor JC, Valga F, Vidaurreta M, Fernández-Pérez C, Barrientos A.

Nephrol Dial Transplant. 2012 Nov;27(11):4227-35. doi: 10.1093/ndt/gfs409.

17.

Kidney function and prevalent and incident frailty.

Dalrymple LS, Katz R, Rifkin DE, Siscovick D, Newman AB, Fried LF, Sarnak MJ, Odden MC, Shlipak MG.

Clin J Am Soc Nephrol. 2013 Dec;8(12):2091-9. doi: 10.2215/CJN.02870313. Epub 2013 Oct 31.

18.

Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging.

Semba RD, Fink JC, Sun K, Windham BG, Ferrucci L.

J Ren Nutr. 2010 Mar;20(2):74-81. doi: 10.1053/j.jrn.2009.08.001. Epub 2009 Oct 22.

19.

Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals.

Brown JR, Katz R, Ix JH, de Boer IH, Siscovick DS, Grams ME, Shlipak M, Sarnak MJ.

Clin J Am Soc Nephrol. 2014 Feb;9(2):239-46. doi: 10.2215/CJN.05830513. Epub 2013 Nov 21.

20.

Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study.

Bash LD, Erlinger TP, Coresh J, Marsh-Manzi J, Folsom AR, Astor BC.

Am J Kidney Dis. 2009 Apr;53(4):596-605. doi: 10.1053/j.ajkd.2008.10.044. Epub 2008 Dec 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk